eurofeedback for treatment of post-COVID-19 complications

Not Applicable

Completed

• Conditions: Post-COVID complications; Infections and Infestations

• Registration Number: ISRCTN49037874
• Lead Sponsor: Charles University

Brief Summary

2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35895740/ (added 28/07/2022)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2021-12-22
• Study Start: 2022-04-29
• Last Update Posted: 17 October 2022

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 17

Inclusion Criteria

1. Age 18-65 years
2. A positive history of SARS-CoV-2 infection confirmed by a positive antigen/reverse transcription polymerase chain reaction (RT-PCR)/antibody test
3. At least one of the following symptoms: insomnia, headaches/migraines, dizziness, seizures, fatigue, depression, and anxiety that were not present prior to SARS-CoV-2 infection
4. The specific symptoms should have been present or persisted for at least 3 months after confirmed SARS-CoV-2 infection and should not have been attributable to any other neurological disease prior to COVID-19
5. Being free of neurological/systemic health problems prior to SARS-CoV-2
6. Being medication-free (or medically stable in type and dosage of the drug for at least 3 months prior to neurofeedback experiment)

Exclusion Criteria

1. Younger than 18 years
2. No positive anamnesis of SARS-CoV-2 infection confirmed by positive antigen/RT-PCR/antibody test
3. Absence of post-COVID complications
4. The presence of neurological/systemic disorders prior to SARS-CoV-2 infection

Study & Design

• Study Type: Interventional
• Study Design: Not specified